Secondary Logo

Journal Logo

Lung Cancer

  • Creator:   Chinese Medical Journal
  • Updated:   4/25/2021
  • Contains:  8 items
Lung cancer is among the most common malignant tumors that cause serious harm to humans. Despite the successes of chemotherapy, radiotherapy, and targeted therapy, the prognosis of lung cancer remains unsatisfactory. Fortunately, patients with lung cancer have found hope in immunotherapy, particularly, in immune checkpoint inhibitors (ICIs). ICIs in immunotherapy for lung cancer have shifted from back-line treatment to first-line treatment, from palliative treatment to consolidation treatment, from advanced lung cancer therapy to early neoadjuvant therapy, and towards precise individualized treatment. However, immunotherapy involves many problems that should be considered and resolved. This collection focuses on the recent advancements and challenges of ICIs in patients with lung cancer.

Diffusion kurtosis imaging: correlation analysis of quantitative model parameters with molecular features in advanced lung adenocarcinoma

Peng, Qin; Tang, Wei; Huang, Yao; More

Chinese Medical Journal. 133(20):2403-2409, October 20, 2020.

Highlight: This study conducted a preliminary evaluation of the correlation of non-Gaussian diffusion kurtosis imaging (DKI) parameters with expression of molecular markers (EGFR, ALK, Ki-67 protein) in patients with advanced lung adenocarcinoma, using routine diffusion-weighted imaging as the reference standard.

Mechanisms of resistance to immune checkpoint inhibitors and strategies to reverse drug resistance in lung cancer

Qian, Fang-Fei; Han, Bao-Hui

Chinese Medical Journal. 133(20):2444-2455, October 20, 2020.

Highlight: This article reviewed the molecular mechanism of immune checkpoint inhibitor resistance and various combination strategies to overcome resistance, in order to expand the beneficial population and enable precision medicine.

Emerging immunotherapy targets in lung cancer

Zhu, Hao-Hua; Feng, Yu; Hu, Xing-Sheng

Chinese Medical Journal. 133(20):2456-2465, October 20, 2020.

Highlight: This review summarizes the molecular features, biological function, and clinical significance of several novel checkpoints that have important roles in lung cancer immune responses beyond the CTLA-4 and PD-1/PD-L1 axes, including the markers of co-inhibitory and co-stimulatory T lymphocyte pathways and inhibitory markers of macrophages and natural killer cells.

Biomarkers or factors for predicting the efficacy and adverse effects of immune checkpoint inhibitors in lung cancer: achievements and prospective

Shi, Wen-Jia; Zhao, Wei

Chinese Medical Journal. 133(20):2466-2475, October 20, 2020.

Highlight: This review presented a detailed introduction of existing biomarkers concerning tumor abnormality and host immunity. PD-L1 expression, tumor mutation burden, neoantigens, specific gene mutations, circulating tumor DNA, human leukocyte antigen class I, tumor microenvironment, peripheral inflammatory cells, and microbiome are discussed in detail.

Circulating tumor DNA in lung cancer: real-time monitoring of disease evolution and treatment response

Li, Rui-Yu; Liang, Zhi-Yong

Chinese Medical Journal. 133(20):2476-2485, October 20, 2020.

Highlight: This review mainly focuses on the clinical application of circulating tumor DNA (ctDNA) in lung cancer, including screening and early diagnosis, predicting prognosis and staging, profiling cancer-associated mutation and structural alterations, heterogeneity, relapse, treatment response, and resistance.

Serum microRNA expression profiling revealing potential diagnostic biomarkers for lung adenocarcinoma

Shan, Xia; Zhang, Lan; Zhu, Dan-Xia; More

Chinese Medical Journal. 133(21):2532-2542, November 5, 2020.

Highlight: This four-stage study aimed at finding serum miRNAs as potential biomarkers for lung adenocarcinoma (LA) diagnosis.

Clinical application and mechanism of traditional Chinese medicine in treatment of lung cancer

Su, Xiao-Lin; Wang, Jiang-Wei; Che, Hui; More

Chinese Medical Journal. 133(24):2987-2997, December 20, 2020.

Highlight: This review summarized the recent 5 years of different research progress on clinical applications and antitumor mechanisms of traditional Chinese medicine in the treatment of lung cancer.